Read news from:
Austria
SHARE
COPY LINK

NOVARTIS

Novartis drug firm faces Turkey bribe probe

Turkish prosecutors have launched an investigation into alleged corruption by Swiss pharmaceutical giant Novartis, the Anatolia news agency said on Friday.

Published: 2 April 2016 10:15 CEST
Novartis drug firm faces Turkey bribe probe
A building at Novartis's campus in Basel, Switzerland. Photo: Novartis
The probe follows reports in the Turkish press which alleged Novartis paid bribes of $85 million (75 million euros) via a consulting company to representatives of the Turkish health ministry in order to “unfairly acquire a market share”.
   
Contacted by AFP, Novartis said it had no comment on the report. But it said a previous probe into Novartis in Turkey, sparked by a complaint by a whistleblower, was dropped by Turkish authorities after
Novartis's own internal investigation in 2014 found no wrongdoing.
   
The drugmaker said last week it had reached a deal with US authorities to pay $25 million (22.4 million euros) to settle claims that its Chinese units bribed healthcare professionals to boost sales.
 
And the US last year fined the group $390 million for granting kickbacks to pharmacies that recommended the company's drugs.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

NOVARTIS

Switzerland’s Novartis to help make Pfizer-BioNTech Covid vaccine

Swiss pharmaceuticals giant Novartis said Friday it had signed an initial agreement to help produce the Pfizer-BioNTech vaccine against Covid-19, as countries scramble to boost supplies.

Published: 29 January 2021 15:53 CET
Switzerland's Novartis to help make Pfizer-BioNTech Covid vaccine
Novartis will help manufacture Pfizer vaccine. Photo by AFP.

The rare act of cooperation — in an industry usually marked by cut-throat competition — comes after French pharma group Sanofi announced earlier this week that it would also team up with rivals Pfizer and BioNTech to help produce 125 million doses of their jab.

The two-dose vaccine, which is based on mRNA technology, has been shown to be around 95 percent effective and has been approved for use by the World Health Organization and in some 50 countries.

But it is in limited supply as nations around the world race to immunise their populations against the coronavirus, which has killed nearly 2.2 million people in just over a year.

Novartis said in a statement that it would use its sterilised manufacturing facilities at its site in Stein, Switzerland to help produce the Pfizer-BioNTech jabs.

Under the agreement, the company said it would “take bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions for shipment back to BioNTech for their distribution to healthcare system customers around the world”.

Once a final agreement is reached, Novartis said it expected to begin production in the second quarter of the year, with initial shipment of finished product expected in the third quarter.

Steffen Lang, Head of Novartis Technical Operations, stressed that the company was “committed to leverage our manufacturing capabilities to help support the supply of COVID-19 vaccines and therapeutics around the world”.

“We expect this to be the first of a number of such agreements,” he said in the statement.

Novartis said it was already in “advanced discussions” with a number of other companies about with other production tasks, including of mRNA, therapeutic protein and raw material production for Covid vaccines and therapeutics. 

SHOW COMMENTS